If your gastroenterologist has prescribed Entyvio for Crohn's disease and you carry a Blue Cross Blue Shield card, the honest answer to whether your plan covers it is that it depends on which Blue plan you have. Blue Cross Blue Shield is not a single insurer. It is a federation of more than 30 independent, locally operated companies, each setting its own medical policy, formulary, and prior authorization rules. A coverage decision that applies in Massachusetts may not match the rules used by an Anthem plan in Ohio or a Blue plan in Idaho. Understanding that variability is the most useful starting point, because it tells you to look up your own plan's documents rather than trust a national answer.
Why Blue Cross Coverage Varies So Much
Each Blue Cross Blue Shield company writes its own coverage criteria and contracts with its own pharmacy benefit manager, which is the organization that administers drug benefits and often runs the prior authorization process. Many Blue plans use Prime Therapeutics, which describes itself as providing services to several Blue Cross and Blue Shield plans, employers, and union groups. Anthem-affiliated Blue plans frequently use CarelonRx as their pharmacy benefits manager. Because the benefit manager and the local medical policy both shape the rules, two people who both say they "have Blue Cross" can face different formulary tiers, different step therapy requirements, and different paperwork for the same drug.
What Entyvio Is and Why Coverage Is Usually Possible
Entyvio, the brand name for vedolizumab, is an integrin receptor antagonist indicated in adults for moderately to severely active Crohn's disease as well as ulcerative colitis. It works selectively in the gut by blocking the alpha-4-beta-7 integrin, limiting the migration of certain inflammatory white blood cells into intestinal tissue. The standard regimen begins with 300 mg by intravenous infusion at weeks zero, two, and six, then every eight weeks. In 2024 the FDA also approved a subcutaneous maintenance option for Crohn's disease, given after intravenous induction. The American Gastroenterological Association lists vedolizumab among the higher-efficacy options for Crohn's disease, which helps support a coverage request when it is medically appropriate.
Prior Authorization Is the Common Thread
Whatever Blue plan you have, expect prior authorization. Across published Blue Cross policies, Entyvio is treated as a drug that requires review before approval. The Blue Cross Blue Shield Federal Employee Program policy, for example, considers Entyvio medically necessary only when the patient is at least 18, has moderately to severely active Crohn's disease, and has an inadequate response, intolerance, or contraindication to at least one conventional therapy, with a re-evaluation at week 14 to confirm benefit. Blue Cross Blue Shield of Massachusetts similarly requires prior authorization and that the drug be prescribed by a board-certified or eligible gastroenterologist. These details vary, but the pattern of specialist involvement and documented prior treatment is consistent.
Step Therapy and the Medical Versus Pharmacy Benefit
Some Blue plans add step therapy, meaning you may need to try and fail a preferred therapy before Entyvio is approved. The Federal Employee Program policy notes that when Entyvio is adjudicated through the pharmacy benefit, the patient may also need an inadequate response or intolerance to a biologic or targeted synthetic DMARD. Because Entyvio is infused or injected, it can fall under either the medical benefit or the pharmacy benefit depending on your plan and how the drug is obtained. That distinction affects which prior authorization form applies, which specialty pharmacy or infusion site is in network, and how your cost share is calculated. Confirming whether your Entyvio claim runs through the medical or pharmacy side avoids surprises.
How to Find Your Own Blue Plan's Rules
Rather than guessing, go directly to your plan's published documents. Three steps cover most situations.
Locate your specific Blue company on your member card, then search its provider or member site for the vedolizumab or Entyvio medical or pharmacy policy.
Review the current formulary or drug list to see the tier, any step therapy notes, and which specialty pharmacy is required.
Identify your pharmacy benefit manager, often Prime Therapeutics or CarelonRx, since it usually processes the prior authorization.
Your gastroenterologist's office submits the actual request, but knowing the exact criteria in advance lets you confirm your chart documents each requirement. If a request is denied, you have the right to appeal, and a well-documented medical-necessity letter referencing your plan's own policy language is the strongest foundation.
The Bottom Line for Blue Cross Members
There is no single yes or no to whether Blue Cross Blue Shield covers Entyvio for Crohn's. Most Blue plans do cover vedolizumab when it is medically necessary and the prior authorization criteria are met, and the drug's selective mechanism and place among recommended Crohn's therapies generally support that case. What changes from plan to plan is the fine print: the formulary tier, whether step therapy applies, the specialist requirement, and whether the claim runs through the medical or pharmacy benefit. The reliable path is to read your own Blue company's vedolizumab policy and current formulary, confirm your treatment history matches the listed criteria, and work with your gastroenterologist to assemble documentation before the request goes in. That preparation travels with you regardless of which Blue plan you hold.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.